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ABSTRACT
Objective To investigate the morphological and
functional outcomes after intravitreal ranibizumab
injections for choroidal neovascularisation (CNV)
complicating geographic atrophy (GA).
Design Retrospective, interventional, consecutive case
series.
Methods We reviewed the charts of all consecutive
patients with GA due to age-related macular
degeneration (AMD), who received intravitreal
ranibizumab injections for the development of CNV at
least 24 months earlier.
Results 21 treatment-naive eyes of 21 consecutive
patients (4 men, 17 women, mean age 86.9±1.6 years)
were included. In 95.2% of eyes a type 2 CNV was
present, extrafoveal in 42.8% of cases. After a mean of
5.0±0.87 (range 1–20) intravitreal ranibizumab
injections, best-corrected visual acuity (BCVA)
signiﬁcantly worsened at the 24-month follow-up visit
(0.73±0.05 vs 0.88±0.08 logMAR, respectively;
p=0.01). A signiﬁcant reduction of intraretinal cystic
lesions, subretinal ﬂuid and pigment epithelium
detachment (p<0.001) and a signiﬁcant increase of GA
area (p=0.003) were present at last visit.
Conclusions Ranibizumab treatment of GA-associated
CNVs provides no BCVA improvement at 24 months
follow-up despite an anatomic response of CNV. Low
effectiveness of ranibizumab in these cases is likely due
to GA progression.
INTRODUCTION
Age-related macular degeneration (AMD) is the
leading cause of blindness and visual disability in
patients over the age of 55 years in developed
countries.1 It has been subdivided into three cat-
egories2: (1) early AMD, characterised by multiple
small drusen (<63 μm) or intermediate drusen
(≥63 μm and <125 μm) with no evidence of
advanced AMD; (2) intermediate AMD charac-
terised by extensive intermediate drusen or large
drusen (≥125 μm) with no evidence of advanced
AMD; and (3) advanced AMD, characterised by
the presence of one or other of geographic atrophy
(GA) or exudative AMD.
GA is characterised by the presence of a discrete
area of retinal depigmentation at least 175 μm in
diameter with a sharp border and visible choroidal
vessels; it is generally slowly progressive.2
Exudative AMD is characterised by a choroidal
neovascularisation (CNV) developing under the
retina, responsible for serous or haemorrhagic
detachment of either the retinal pigment
epithelium (RPE) or sensory retina, and presence
of subretinal ﬁbrous tissue2; onset of vision loss is
generally acute.
The prevalence of GA is 3.5% in subjects older
than 75 years, and accounts for approximately half
the prevalence of exudative AMD. GA accounts for
approximately 25% of cases with severe central
vision loss. Exudative AMD accounts for approxi-
mately 75% of cases with severe central vision
loss, if untreated. However, in some eyes with GA,
a CNV may develop, thus affecting the natural
history and causing further vision loss.
Ranibizumab (Lucentis, Genentech, South
San Francisco, California, USA), is a recombinant,
humanised, monoclonal antibody antigen-binding
fragment (Fab) that neutralises all biologically
active forms of vascular endothelial growth factor
A (VEGF).3 Intravitreal ranibizumab was the ﬁrst
therapy for exudative AMD that showed, in two
phase III clinical studies, prevention in vision loss,
and improvement in mean visual acuity, in a
remarkable proportion of patients.4 5 These bene-
ﬁts persisted through 24 months of follow-up.
However, these results regard eyes diagnosed exclu-
sively with exudative AMD. To date, there are no
data regarding the effects of intravitreal ranibizu-
mab in eyes with GA that develop CNV in the pro-
gression of the disease.
In this study we investigated the morphological
and functional outcomes after intravitreal ranibi-
zumab injections for CNV complicating GA due to
AMD.
METHODS
We reviewed the charts of all consecutive patients
with GA that developed a CNV and received intra-
vitreal injections of ranibizumab at the University
Eye Clinic of Creteil at least 24 months before. A
written informed consent according to the tenets
of the Declaration of Helsinki was obtained
from each patient enrolled. French Society of
Ophthalmology Ethics Committee approval was
obtained for the retrospective review of data.
Criteria for inclusion were: (1) age ≥50 years; (2)
diagnosis of GA due to AMD, deﬁned as a discrete
area of retinal depigmentation at least 360 μm in
diameter with a sharp border and visible choroidal
vessels; (3) best-corrected visual acuity (BCVA)
better than 20/400 (20 letters) as evaluated by
Early Treatment Diabetic Retinopathy Study
(ETDRS) charts; and (4) presence of newly diag-
nosed active CNV as evaluated with fundus biomi-
croscopy and ﬂuorescein angiography (FA) at least
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24 months earlier. Patients with previous treatment for neovas-
cular AMD in the study eye, refractive error of more than −6
dioptres, CNV attributable to other causes than AMD, active
intraocular inﬂammation or any other retinopathy (such as dia-
betic retinopathy, retinal venous occlusion or epiretinal mem-
brane) in the study eye, were excluded.
At baseline, each patient underwent a detailed medical and
ocular history, a complete ophthalmologic examination (stand-
ard assessment in our clinic) which included slit-lamp biomi-
croscopy, intraocular pressure (IOP) assessment, measurement
of BCVA using standard ETDRS charts, fundus biomicroscopy,
fundus autoﬂuorescence (FAF), FA and spectral-domain optical
coherence tomography (Spectralis HRA+OCT, Heidelberg
Engineering, Heidelberg, Germany).
Initial treatment consisted in one single intravitreal injection
of 0.5 mg/0.05 ml ranibizumab performed by a retinal specialist
according to the usual technique.6 After the initial treatment,
each patient underwent, monthly, a detailed medical and
ocular history, assessment of BCVA using ETDRS charts and
ophthalmic examination, which included slit-lamp biomicro-
scopy, IOP assessment, fundus biomicroscopy and OCT exam-
ination (standard assessment in our clinic).
The patients received further intravitreal injections if any of
the following conditions applied: BCVA loss of at least ﬁve
letters associated with recurrence of ﬂuid within a previously
dry macula as evaluated by OCT; persistence of intra/subretinal
ﬂuid (SRF) as evaluated by OCT; new-onset macular haemor-
rhages. In case of doubtful ﬁndings, FA was performed during
follow-up, and persistence or recurrence of leakage from the
lesions was considered as a retreatment criterion.
Main outcome measures were changes in mean BCVA
(expressed as a logarithm of the minimum angle of resolution
(logMAR)), and in morphological features associated with GA
progression and CNV activity (two graders, GQ and NM), at
24 months from ﬁrst treatment.
As qualitative parameters of GA progression, the foveal
sparing on FAF and SD-OCT images, and the IS/OS layer
status (present or disrupted/absent) at the fovea on SD-OCT
scans were evaluated at the 24-month follow-up visits, and
compared with baseline. SD-OCT was used in combination
with FAF to distinguish whether a hypoautoﬂuorescence was
due to the blocking effect by xanthophylls or to atrophy (loss
of outer retina on SD-OCT scans). Moreover, the development
of an atrophic scar at the CNV (loss of outer retina on
SD-OCT scans) site was evaluated at the 24-month follow-up
visits. As qualitative parameters of CNV response to treatment,
presence of intraretinal cystic lesions, SRF, pigment epithelium
detachment (PED), and ﬁbroglial scar at the fovea (ie. hyper-
reﬂective subretinal lesion), were evaluated on SD-OCT scans
at the 24-month follow-up visits, and compared with baseline.
As a quantitative parameter of GA progression, the GA areas
were measured on FAF frames at the 24-month follow-up
visits, and compared with baseline measurements. The atrophic
areas were outlined (boundaries drawn on FAF images, and
sizes calculation) using the Heidelberg software (Spectralis
Acquisition and Viewing Modules; V.3.2, Heidelberg
Engineering). As a quantitative parameter of CNV response to
treatment, the greatest linear dimensions (GLDs) on late phase
FA frames, and the retinal thickness at the CNV site (deﬁned
by the distance between the inner retinal surface and the inner
aspect of the hyper-reﬂective layer represented by the Bruch’s
membrane/choriocapillaris complex), and the retinal thickness
of the 1-mm central retina (central macular thickness (CMT)
measured using a 19-horizontal lines protocol) on SD-OCT
were measured at the 24-month follow-up visits, and compared
with baseline measurements.
As part of this study, in order to evaluate GA progression
before starting treatment with intravitreal ranibizumab injec-
tions, changes in the GA areas over time were measured on FAF
frames in selected eyes (when previous FAF before the advent
of CNV were available). Enlargement rate was calculated based
on two visits (baseline visit and last follow- up visit). The
change in lesion size between these two visits (last follow-up
and baseline) was divided by the time of follow-up (in years).
Enlargement rate was calculated for lesion size, both on the ori-
ginal area scale and after transforming the measurements to
the square-root scale.
Statistical calculations were performed using SPSS V.17.0.
Comparisons of mean BCVA, and quantitative parameter of GA
progression and CNV activity between baseline and 24-month
follow-up were performed using the paired t test. The χ2 test
was used to assess changes of qualitative parameters of GA pro-
gression and CNV activity from baseline to last visit.
Regression analysis was used to correlate BCVA with morpho-
logical features at baseline and 24-month follow-up. Analysis of
covariance was used to correlate BCVA and site of neovasculari-
sation, and to correlate BCVA and IS/OS layer status (present
or disrupted/absent) at the fovea and at the CNV site. To quan-
tify inter-grader concordance concerning the width of area of
foveal sparing as measured with FAF and SD-OCT and the
measurement of GA area, Cohen k coefﬁcients for the reliability
of nominal data,7, the k0 coefﬁcient for pooled classiﬁcation
proportions8 and the k00 coefﬁcient adjusted for prevalence
according to Byrt et al 9 were computed. The chosen level of
statistical signiﬁcance was p<0.05.
RESULTS
Demographics and clinical data of the study population
Twenty-one treatment-naive eyes of 21 consecutive patients
(4 men, 17 women, mean age 86.9±1.6 years) with CNV com-
plicating GA due to AMD met the inclusion criteria and were
included in the analysis. Most fellow eyes also presented GA
without CNV (17 out of 21); four fellow eyes presented active
or ﬁbrovascular CNV. Clinical data are summarised in tables 1
and 2.
All eyes presented a type 2 CNV (sub-neurosensory, well deli-
neated, classic or visible on FA) (ﬁgures 1 and 2), except 1/21
eyes that showed a type 1 CNV (sub-RPE, indistinct or occult
on FA) (ﬁgures 3 and 4). In 12/21 eyes, the CNV was located in
the sub/juxtafoveal area (ﬁgures 1 and 2), while in 9/21 eyes it
was extrafoveal (ﬁgures 1 and 2). Patients received a mean of
5.0±0.87 (range 1–20) intravitreal ranibizumab injections
during 24 months. No injection-related complications such as
Table 1 Clinical data at baseline and 24-month follow-up visit of
21 eyes with CNV complicating GA due to age-related macular
degeneration
Baseline Month 24 p Value
BCVA (logMAR) 0.73±0.05 0.88±0.08 0.01
GA area (μm2) 5613.6±896.9 8956.1±1268 0.003
CNV GLD (μm) 844.8±169.0 531.2±168.6 0.02
Retinal thickness at CNV (μm) 252.2±13.0 187.5±14.1 <0.001
CMT (μm) 307.3±20.5 256.1±13.1 0.01
BCVA, best-corrected visual acuity; CMT, central macular thickness; CNV, choroidal
neovascularisation; GA, geographic atrophy; GLD, greatest linear dimension;
logMAR, logarithm of the minimum angle of resolution.
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cataract, retinal detachment, or endophthalmitis were observed
during the study period.
Baseline BCVA (0.73±0.05 logMAR (47.9±2.2 ETDRS
letters)) improved but not signiﬁcantly at the 3-month
follow-up (0.66±1.2 logMAR (52±3.2 ETDRS letters); p>0.05),
but worsened at the 24-month follow-up visit (0.88±0.08
logMAR (41.0±1.8 ETDRS letters); p=0.01). Correlation
between baseline and 24-month follow-up BCVA was statistic-
ally signiﬁcant (R=0.7, p<0.001), correlation of 24-month
BCVA with patient’s age was R=0.1, p=0.5, while correlation
between number of injections and 24-month BCVAwas R=0.4,
p=0.02. BCVA reduction at 24 months was signiﬁcantly corre-
lated with both subfoveal CNVand extrafoveal CNV (p<0.001).
Analysis of qualitative and quantitative parameters of GA
progression
Overall, on the basis of combined FAF and SD-OCT images,
17/21 eyes (80.9%) and 15/21 eyes (71.4%) presented a foveal
Table 2 Demographics and response to intravitreal ranibizumab
injections in 21 patients with choroidal neovascularisation complicating
GA due to age-related macular degeneration
Case
Age
(years) Gender
BCVA,
baseline
(ETDRS
letters)
BCVA, 24
months
(ETDRS
letters)
FAF GA
area,
baseline
(μm2)
FAF GA
area,
24 months
(μm2)
#1 86 F 48 42 4500 8916
#2 87 F 47 43 5322 10020
#3 88 F 47 45 5898 9920
#4 89 F 49 43 4908 9550
#5 85 F 49 40 6131 9210
#6 85 F 50 40 5622 9710
#7 87 F 43 58 5610 8380
#8 85 M 46 41 6360 9595
#9 88 F 51 34 5980 7665
#10 86 F 48 37 6162 10832
#11 87 F 44 42 5829 9230
#12 85 M 50 32 3232 5820
#13 87 F 47 39 5426 7280
#14 90 F 45 38 4532 8190
#15 86 F 48 42 6702 9490
#16 85 F 49 41 6415 10650
#17 85 M 47 41 7504 9632
#18 89 M 50 39 5813 8910
#19 89 F 47 40 5040 7710
#20 88 F 51 41 5700 10200
#21 89 F 51 40 5192 7170
BCVA, best-corrected visual acuity; ETDRS, early treatment diabetic retinopathy
study; FAF, fundus autofluorescence, GA, geographic atrophy.
Figure 1 Fundus autoﬂuorescence (FAF), ﬂuorescein angiography (FA)
and spectral-domain optical coherence tomography (SD-OCT) of case
#7 at baseline. Right eye FAF shows a large area of foveal sparing
geographic atrophy due to age-related macular degeneration (top left
panel). FA shows late leakage from the juxtafoveal type 2 (visible)
choroidal neovascularisation (CNV) (top right panel, arrow). SD-OCT
shows exudative retinal changes and retinal thickening associated with
the CNV (bottom panel, arrowhead).
Figure 2 Fundus autoﬂuorescence (FAF), ﬂuorescein angiography (FA)
and spectral-domain optical coherence tomography (SD-OCT) of case
#7 at 24 months from baseline examination, after three intravitreal
injections of ranibizumab. Right eye FAF shows enlargement, in the
extrafoveal region, of geographic atrophy due to age-related macular
degeneration (top left panel, asterisk). FA shows absence of leakage
from the site where the choroidal neovascularisation (CNV) developed
24 months before (top right panel). SD-OCT shows the absence of
exudative retinal changes and complete regression of the CNV (bottom
panel).
Figure 3 Fundus autoﬂuorescence (FAF), ﬂuorescein angiography (FA)
and spectral-domain optical coherence tomography (SD-OCT) of case
#3 at baseline. Left eye FAF shows a geographic atrophy due to
age-related macular degeneration within the macula (top left panel). FA
shows an extrafoveal type 1 (occult) choroidal neovascularisation (CNV)
(top right panel, arrow). SD-OCT shows pigment epithelium detachment
and retinal thickening associated with the CNV (bottom panel,
arrowhead).
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sparing GA at baseline and at 24 months, respectively
(p=0.005). Both eyes developing foveal involvement at
24 months, had subfoveal CNV at baseline (suggesting that it
was due to scar of CNV). Inter-individual agreement between
graders for foveal sparing as measured with FAF and SD-OCT,
with consistent gradings, was signiﬁcant (k=k0=0.8, p=0.001,
k00=0.7). The IS/OS layer, as evaluated by SD-OCT at the
fovea, was present in 4/21 eyes at baseline; in all of them, the
IS/OS layer became disrupted/absent at 24 months. Correlation
between IS/OS layer status (present or disrupted/absent) at the
fovea and BCVA at baseline and at 24-month visit was signiﬁ-
cant (p<0.001). Eleven of 21 eyes (52.4%) developed an atro-
phic scar at the CNV site scans at the 24-month follow-up
visits. The mean GA area, as evaluated on FAF frames, signiﬁ-
cantly increased from 5613±896 μm2 at baseline to 8956
±1268 μm2 at 24 months (p=0.003). Inter-individual agree-
ment between graders for GA area, with consistent gradings,
was signiﬁcant (k=k0=0.9, p=0.001, k00=0.7).
In 8/21 eyes GA progression was present on consecutive FAF
frames before treatment, with a mean enlargement rate of
0.9 mm2/year (range 0.05–1.8 mm2/year). After treatment with
ranibizumab an increased enlargement rate was noticed,
although not signiﬁcant (1.1 mm2/year; range 0.07–2.1 mm2/
year, p=0.1).
Analysis of qualitative and quantitative parameters of CNV
response to treatment
Overall, on SD-OCT scans passing throughout the fovea, intrar-
etinal cystic lesions were present in 5/21 eyes (23.8%) at base-
line and in 2/21 eyes (9.5%) at month 24 (p<0.001), SRF was
present in 4/21 eyes (19.0%) at baseline and in 1/21 eyes (4.7%)
at month 24 (p<0.001), and PED was present in 1/21 eyes
(4.7%) at baseline and in 0/21 eyes at month 24 (p<0.001).
Three of 21 eyes (14.3%) and 11/21 eyes (52.4%) developed a
ﬁbroglial scar at the fovea and the CNV site scans at
24 months, respectively. No signiﬁcant correlation was found
between IS/OS layer status (present or disrupted/absent) at the
CNV site and BCVA at baseline and 24 months (p>0.05).
Mean GLD, as evaluated on late phase FA frames, and retinal
thickness at the CNV site and CMT, as evaluated on SD-OCT,
changed from 844.8±169.0 μm, 252.2±13.0 μm and 307.3
±20.5 μm at baseline to 531.2±168.6 μm (p=0.02), 187.5
±14.1 μm (p<0.001) and 256.1±13.1 μm (p=0.01) at the
24-month visit.
DISCUSSION
In this study we retrospectively investigated the effects of
intravitreal ranibizumab injections in eyes with GA compli-
cated by CNV. Overall, 21 eyes with GA due to AMD and
newly diagnosed active CNV, were analysed with respect to
morphological and functional changes over 24 months. Despite
a signiﬁcant reduction of CNV activity, a reduction of BCVA
was present at the 24-month visit (p=0.01). To the best of our
knowledge, there are no published data on the management of
patients showing the coexistence of the two forms of advanced
AMD in the same eye.
In the MARINA trial,4 and the ANCHOR trial,5 the ﬁnal
mean BCVA at 24 months improved by 7.2 letters, and 10.7
letters, respectively, after monthly intravitreal injections of
ranibizumab. In the current study, using a variable-dosing
regimen, mean BCVA at 24 months decreased by eight letters,
suggesting less favourable functional outcomes in the treat-
ment of AMD eyes with CNV complicating GA by intravitreal
ranibizumab injections. Similarly, less favourable functional
outcomes appeared in the current study, compared with the
MARINA trial, as regards clinically signiﬁcant improvement in
BCVA, deﬁned as a gain of 15 or more letters (4.76% of eyes,
and 34% of eyes, respectively), and decrease of 15 or less letters
(47.6% of eyes, and 91% of eyes, respectively). Our functional
outcomes also look less favourable when compared with the
PrONTO study,10 in which the ﬁnal mean BCVA at 24 months
improved by 11.1 letters, after a variable-dosing regimen of
intravitreal ranibizumab, compared with the six letters’
decrease of the current study. Moreover in the PrONTO study,
97.5% of eyes avoided a 15-letter BCVA decrease (47.6% of eyes
in the current study), and 43% of eyes gained at least 15 letters
of BCVA (4.76% of eyes in the current study). Interestingly, in
the current series, patients received fewer intravitreal ranibizu-
mab injections compared with the PrONTO study (5.0 and
9.9, respectively).
In the study of Rothenbuehler et al,11 similarly to the current
series, patients received one injection of ranibizumab followed
by a pro-re-nata regimen. In their prospective analysis, the
authors found that after 24 months and a mean of 9.9 intravi-
treal ranibizumab injections, 30% of eyes gained >15 letters,
and 55% of eyes lost or gained <15 letters. Therefore, our func-
tional outcomes appear less favourable than those of
Rothenbuehler et al.11
Nonetheless, in our study, we found an improvement in both
qualitative and quantitative morphological parameters of CNV
activity, from baseline to 24 months. A signiﬁcant reduction of
intraretinal cystic lesions, SRF and PED was present at the
24-month visit. GLD, CMT and CNV thickness also signiﬁ-
cantly reduced at the 24-month visit. Therefore, the less favour-
able functional outcomes of our study (despite overall good
morphological outcomes), compared with previous studies of
intravitreal ranibizumab injections for exudative AMD, might
be due to the intervening atrophic changes secondary to GA. In
fact, an overall disruption of the IS/OS layer at the fovea and a
signiﬁcant increase of the GA area were present at the
24-month visit. Moreover, a high correlation between baseline
and the 24-month follow-up BCVA was found, possibly sug-
gesting an important role of pre-existing atrophy in the BCVA
response.
The signiﬁcant increase in GA area at month 24 in our series
may simply represent natural disease progression. However,
Figure 4 Fundus autoﬂuorescence (FAF), ﬂuorescein angiography (FA)
and spectral-domain optical coherence tomography (SD-OCT) of case
#3 at 24 months from baseline examination, after 20 intravitreal
injections of ranibizumab. Left eye FAF (top left panel), FA (top right
panel) and SD-OCT (bottom panel) show a large ﬁbroglial scar involving
the fovea and the temporal macula (the site where the CNV developed
24 months earlier).
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based on the data from selected eyes (when previous FAF
before the advent of CNV were available), GA progression rate
seems increased after anti-VEGF treatment. These data,
together with recently published ﬁndings from the Comparison
of Age-related Macular Degeneration Treatments Trials CATT
study,12 suggest that progression of GA may be somehow
related to the anti-VEGF treatment.
In the current series, improvement in qualitative and quanti-
tative parameters of CNV activity were achieved by means of
far less intravitreal injections of ranibizumab over 24 months
compared with previous studies.10 11 This might be due to a
reduced expression of VEGF in the retina, responsible for less
CNV activity.13 In GA, a possible mechanism suggested for
CNV development is the over-production of VEGF by the RPE
following the choriocapillaries degeneration that triggers chor-
oidal neovascularisation and wet AMD. However, the overall
production of VEGF would be limited by RPE cells loss asso-
ciated with GA. Consequently, fewer intravitreal injections of
ranibizumab would succeed in determining regression of CNV
and associated exudative changes.
Our study has several limitations, mainly due the retrospect-
ive nature of the analysis, and the small number of studied
eyes. Moreover, the absence of a control group does not allow
evaluation of the possible effects of anti-VEGF treatment on
GA progression. Further investigations are needed to improve
our knowledge regarding the efﬁcacy and safety of intravitreal
ranibizumab in the management of CNV complicating GA.
In conclusion, intravitreal ranibizumab injections may repre-
sent a valuable therapeutic option for CNV complicating GA.
Good morphological outcomes are achieved with less treat-
ments compared with exudative AMD. Functional outcomes
might be limited by the intervening atrophic changes secondary
to GA.
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